Literature DB >> 34424771

Applying Decision Analysis to Inform the US Food and Drug Administration's Benefit-Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS.

Leila G Lackey1, Christine E Garnett2, Fred Senatore2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34424771      PMCID： PMC8422229          DOI： 10.1161/CIRCULATIONAHA.120.053294

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   39.918


× No keyword cloud information.
  4 in total

1.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

2.  Ticagrelor in Patients with Stable Coronary Disease and Diabetes.

Authors:  P Gabriel Steg; Deepak L Bhatt; Tabassome Simon; Kim Fox; Shamir R Mehta; Robert A Harrington; Claes Held; Marielle Andersson; Anders Himmelmann; Wilhelm Ridderstråle; Maria Leonsson-Zachrisson; Yuyin Liu; Grzegorz Opolski; Dmitry Zateyshchikov; Junbo Ge; José C Nicolau; Ramón Corbalán; Jan H Cornel; Petr Widimský; Lawrence A Leiter
Journal:  N Engl J Med       Date:  2019-09-01       Impact factor: 91.245

3.  Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.

Authors:  Praveen Thokala; Nancy Devlin; Kevin Marsh; Rob Baltussen; Meindert Boysen; Zoltan Kalo; Thomas Longrenn; Filip Mussen; Stuart Peacock; John Watkins; Maarten Ijzerman
Journal:  Value Health       Date:  2016-01-08       Impact factor: 5.725

4.  FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals.

Authors:  Leila Lackey; Graham Thompson; Sara Eggers
Journal:  Ther Innov Regul Sci       Date:  2020-08-10       Impact factor: 1.778
  4 in total
  2 in total

1.  Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities.

Authors:  Orin Chisholm; Patrick Sharry; Lawrence Phillips
Journal:  Front Med (Lausanne)       Date:  2022-01-12

2.  Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.

Authors:  Jonathan Mauer; Kristin Bullok; Stephen Watt; Ed Whalen; Leo Russo; Rod Junor; John Markman; Brett Hauber; Tommi Tervonen
Journal:  Br J Clin Pharmacol       Date:  2022-04-08       Impact factor: 3.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.